Luis Paz-Ares

Dr. Luis Paz-Ares


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
LPLuis Paz-Ares
Luis Paz-Ares
TKTae Min Kim
Tae Min Kim
DVDavid Vicente
David Vicente
EFEnriqueta Felip
Enriqueta Felip
DLDae Ho Lee
Dae Ho Lee
BCByoung Chul Cho
Byoung Chul Cho

1 February 2019 in Annals of Oncology
Verified
Journal Article
Closed access
JZJ. Zugazagoitia
J. Zugazagoitia
IRI. Ramos
I. Ramos
JTJ.M. Trigo
J.M. Trigo
MPM. Palka
M. Palka
AGA. Gómez-Rueda
A. Gómez-Rueda
LPLuis Paz-Ares
Luis Paz-Ares
Approximately 30% of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield insufficient tissue for successful molecular subtyping. We have analyzed the clinical utility of next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA) in patients with inadequate tumor samples for tissue genotyping. We conducted the study in a multi-institutional prospective cohort of clinically unselected patients with advanced-stage lung adenocarcinomas with insufficient tissue for EGFR, ALK or ROS1 genotyping across 12 Spanish institutions (n = 93). ctDNA NGS was carried out by Guardant Health (Guardant360, Redwood City, CA), using a hybrid-capture-based 73-gene panel. Variants were deemed actionable if they were part of the OncoKB precision oncology knowledge database and classified in four levels of actionability based on their clinical or preclinical evidence for drug response. Eighty-three out of 93 patients (89%) had detectable levels of ctDNA. Potentially actionable level 1-4 genomic alterations were detected in 53 cases (57%), of which 13 (14%) had level 1-2A alterations (Food and Drug Administration-approved and standard-care biomarkers according to lung cancer guidelines). Frequencies of each genomic alteration in ctDNA were consistent with those observed in unselected pulmonary adenocarcinomas. The majority of the patients (62%), particularly those with actionable alterations (87%), had more than one pathogenic variant in ctDNA. The median turnaround time to genomic results was 13 days. Twelve patients (13%) received genotype-matched therapies based on ctDNA results, deriving the expected clinical benefit. Patients with co-occurring pathogenic alterations had a significantly shorter median overall survival as compared with patients without co-occurring pathogenic alteration (multivariate hazard ratio = 5.35, P = 0.01). Digital NGS of ctDNA in lung cancers with insufficient tumor samples for tissue sequencing detects actionable variants that frequently co-occur with other potentially clinically relevant genomic alterations, allowing timely initiation of genotype-matched therapies.

1 August 2019 in Lung Cancer
Verified
Journal Article
Closed access
JZJon Zugazagoitia
Jon Zugazagoitia
AGAna Gómez-Rueda
Ana Gómez-Rueda
EJEloisa Jantus-Lewintre
Eloisa Jantus-Lewintre
DIDolores Isla
Dolores Isla
CCCarlos Camps
Carlos Camps
PGPilar Garrido
Pilar Garrido

31 March 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
EPElena Prieto-García
Elena Prieto-García
CDC. Vanesa Díaz-García
C. Vanesa Díaz-García
AAAlba Agudo-López
Alba Agudo-López
VPVirginia Pardo-Marqués
Virginia Pardo-Marqués
IGInés García-Consuegra
Inés García-Consuegra
MAM. Teresa Agulló-Ortuño
M. Teresa Agulló-Ortuño
One key feature of pancreatic ductal adenocarcinoma (PDAC) is a dense desmoplastic reaction that has been recognized as playing important roles in metastasis and therapeutic resistance. We aim to study tumor–stromal interactions in an in vitro coculture model between human PDAC cells (Capan-1 or PL-45) and fibroblasts (LC5). Confocal immunofluorescence, Enzyme-Linked Immunosorbent Assay (ELISA), and Western blotting were used to evaluate the expressions of activation markers; cytokines arrays were performed to identify secretome profiles associated with migratory and invasive properties of tumor cells; extracellular vesicle production was examined by ELISA and transmission electron microscopy. Coculture conditions increased FGF-7 secretion and α-SMA expression, characterized by fibroblast activation and decreased epithelial marker E-cadherin in tumor cells. Interestingly, tumor cells and fibroblasts migrate together, with tumor cells in forming a center surrounded by fibroblasts, maximizing the contact between cells. We show a different mechanism for tumor spread through a cooperative migration between tumor cells and activated fibroblasts. Furthermore, IL-6 levels change significantly in coculture conditions, and this could affect the invasive and migratory capacities of cells. Targeting the interaction between tumor cells and the tumor microenvironment might represent a novel therapeutic approach to advanced PDAC.